BR112016017806B1 - Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas - Google Patents

Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas Download PDF

Info

Publication number
BR112016017806B1
BR112016017806B1 BR112016017806-8A BR112016017806A BR112016017806B1 BR 112016017806 B1 BR112016017806 B1 BR 112016017806B1 BR 112016017806 A BR112016017806 A BR 112016017806A BR 112016017806 B1 BR112016017806 B1 BR 112016017806B1
Authority
BR
Brazil
Prior art keywords
cells
cell
antigen
gene
car
Prior art date
Application number
BR112016017806-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016017806A2 (pt
Inventor
Philippe Duchateau
Laurent Poirot
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016017806(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis filed Critical Cellectis
Publication of BR112016017806A2 publication Critical patent/BR112016017806A2/pt
Publication of BR112016017806B1 publication Critical patent/BR112016017806B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016017806-8A 2014-02-14 2015-02-13 Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas BR112016017806B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470076 2014-02-14
DKPA201470076 2014-02-14
PCT/EP2015/053162 WO2015121454A1 (en) 2014-02-14 2015-02-13 Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

Publications (2)

Publication Number Publication Date
BR112016017806A2 BR112016017806A2 (pt) 2017-10-10
BR112016017806B1 true BR112016017806B1 (pt) 2023-05-02

Family

ID=50114255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017806-8A BR112016017806B1 (pt) 2014-02-14 2015-02-13 Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas

Country Status (19)

Country Link
US (3) US10836998B2 (https=)
EP (2) EP3505623B1 (https=)
JP (1) JP6673838B2 (https=)
KR (1) KR102157924B1 (https=)
CN (1) CN106029875B (https=)
AU (1) AU2015216875B2 (https=)
BR (1) BR112016017806B1 (https=)
CA (1) CA2937711C (https=)
DK (2) DK3105317T3 (https=)
ES (2) ES3063961T3 (https=)
HU (1) HUE041497T2 (https=)
IL (1) IL246645B (https=)
MX (1) MX378913B (https=)
NO (1) NO20161276A1 (https=)
PL (1) PL3105317T3 (https=)
PT (1) PT3105317T (https=)
RU (1) RU2714258C2 (https=)
TR (1) TR201819571T4 (https=)
WO (1) WO2015121454A1 (https=)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2015075195A1 (en) * 2013-11-22 2015-05-28 Cellectis Method of engineering chemotherapy drug resistant t-cells for immunotherapy
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
TWI719942B (zh) * 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
KR102558502B1 (ko) 2014-12-05 2023-07-20 시티 오브 호프 Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포
FI3240805T3 (fi) 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
EP3062105A1 (en) * 2015-02-26 2016-08-31 Université de Bretagne Occidentale (U.B.O.) Processes for the diagnosis, prognosis and monitoring of the progression of Chronic Lymphoid Leukaemia (CLL) and/or of Systemic Lupus Erythematosus (SLE) using membrane STIM 1
JP7237449B2 (ja) 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
JP2018509148A (ja) 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
HK1255161A1 (zh) * 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
JP6816133B2 (ja) 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
PL3368571T3 (pl) 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10941381B2 (en) 2015-11-19 2021-03-09 Versiti Blood Research Institute Foundation, Inc. Method of manufacturing dual-specific T-cells for use in cancer immunotherapy
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
CN108699159B (zh) * 2016-02-15 2022-07-29 地方独立行政法人神奈川县立病院机构 膜型粘蛋白样蛋白质的识别及其医疗应用
WO2017149122A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
WO2017177175A1 (en) * 2016-04-07 2017-10-12 The George Washington University Methods and compositions targeting retroviral latency
WO2017178586A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
CA3021634A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
US20190136230A1 (en) * 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
US20200208111A1 (en) * 2016-06-09 2020-07-02 Branden S. Moriarity Genome-edited nk cell and methods of making and using
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102546839B1 (ko) * 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
BR112019002779A2 (pt) 2016-08-12 2019-05-14 Toolgen Incorporated elemento imunorregulador manipulado e imunidade alterada por este
IL308824A (en) * 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017319702B2 (en) 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CA3038532A1 (en) 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
AU2017342176A1 (en) * 2016-10-10 2019-05-02 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
CN106544321B (zh) * 2016-10-13 2019-01-29 北京艺妙神州医疗科技有限公司 通用型car-t细胞及其制备方法和用途
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
EP3535423B1 (en) * 2016-11-07 2022-01-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selecting therapy for a cancer patient
EP3538112B1 (en) * 2016-11-09 2026-02-25 Musc Foundation for Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
EP3538550A1 (en) * 2016-11-10 2019-09-18 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Or10h1 modulators and uses thereof
EP3321280B8 (en) * 2016-11-10 2021-03-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
NZ752984A (en) 2016-11-22 2026-03-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
WO2018104562A1 (en) * 2016-12-09 2018-06-14 Onkimmune Limited Engineered natural killer cells and uses thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3568416A4 (en) 2017-01-13 2020-07-08 Celdara Medical, LLC TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
US10440535B2 (en) 2017-01-25 2019-10-08 The George Washington University System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets
US20200306375A1 (en) * 2017-02-22 2020-10-01 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
AU2018225164A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
AU2018246377B2 (en) 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
JP7235391B2 (ja) 2017-05-08 2023-03-08 ツールゲン インコーポレイテッド 人工的に操作された免疫細胞
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US12384830B2 (en) * 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
CN106978445A (zh) * 2017-06-12 2017-07-25 内蒙古大学 CRISPER‑Cas9系统介导的山羊EDAR基因敲除的方法
CA3287539A1 (en) * 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
EP3645038B1 (en) 2017-06-30 2026-02-18 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CN107312800B (zh) * 2017-08-01 2020-02-07 北京舜雷科技有限公司 能敲低内源性pd-1表达的cik及其制备方法与应用
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN107541526B (zh) * 2017-08-23 2019-12-10 北京瑞健科技有限公司 能敲低内源性ctla4表达的cik及制备方法与应用
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
GB201719169D0 (en) * 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
IL316257A (en) 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
US20230158070A1 (en) * 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
CN112512594A (zh) * 2018-03-23 2021-03-16 瑞非生物科技有限公司 经由基因调节多肽的条件性核定位的基因调节
KR102817092B1 (ko) * 2018-03-29 2025-06-09 페이트 세러퓨틱스, 인코포레이티드 조작된 면역 효과기 세포 및 이의 용도
MA52207A (fr) * 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
US12473342B2 (en) * 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
AU2019261438B2 (en) 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
WO2019222423A1 (en) 2018-05-15 2019-11-21 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN112566643A (zh) * 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
CN110623980A (zh) * 2018-06-25 2019-12-31 深圳宾德生物技术有限公司 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
AU2019302603A1 (en) * 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
CN110819589B (zh) * 2018-08-13 2022-10-11 上海科技大学 一种增强免疫效应细胞功能的方法
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
WO2020072805A1 (en) * 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020092850A1 (en) * 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
WO2020102721A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als)
CN119592592A (zh) * 2018-11-30 2025-03-11 莱蒂恩技术公司 用于用抗cd38免疫治疗来治疗癌症的组合物和方法
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
WO2020194245A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone
WO2020194243A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
WO2020194242A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone
WO2020194244A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib and dexamethasone
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
EP3972585A4 (en) * 2019-05-21 2023-06-21 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy
WO2020252110A1 (en) * 2019-06-14 2020-12-17 Bluebird Bio, Inc. Compositions and methods for treating cancer
AU2020334893A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
KR20220051401A (ko) * 2019-09-06 2022-04-26 크리스퍼 테라퓨틱스 아게 배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
JP2022548925A (ja) * 2019-09-18 2022-11-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021093818A1 (zh) * 2019-11-13 2021-05-20 上海医药集团股份有限公司 Tmem59蛋白二聚体或嵌合表达受体改善t细胞功能
KR20220097985A (ko) * 2019-11-13 2022-07-08 크리스퍼 테라퓨틱스 아게 Car-t 세포의 제조 방법
WO2022250433A1 (ko) * 2021-05-24 2022-12-01 주식회사 센트릭스바이오 Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체
CA3166832A1 (en) * 2020-01-08 2021-07-15 Board Of Regents, The University Of Texas Systems A method of engineering natural killer cells to target cd70-positive tumors
CN111196858B (zh) * 2020-02-05 2021-02-09 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
EP4126243A4 (en) * 2020-03-27 2024-06-12 The Trustees of Indiana University Immunotherapeutic targets in multiple myeloma and methods for their identification
WO2021223705A1 (en) * 2020-05-06 2021-11-11 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
AU2021286655A1 (en) * 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
JP2023530182A (ja) 2020-06-22 2023-07-13 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 多重サブユニットタンパク質モジュール、それを発現する細胞、及びその使用
CN111796101B (zh) * 2020-07-14 2022-08-26 汕头市中心医院 Notch3蛋白表达量检测剂联合cypa蛋白表达量检测剂在预测癌症治疗疗效的用途
CA3200609A1 (en) * 2020-12-02 2022-06-09 Adam Eugene Snook Desmoglein 2-directed chimeric antigen receptor (car) constructs and methods of use
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022210487A1 (ja) * 2021-03-29 2022-10-06 タカラバイオ株式会社 抗原に特異的な受容体を発現する免疫細胞の製造方法
US20240180963A1 (en) * 2021-04-05 2024-06-06 Altheia Science S.R.L. Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens
CA3220226A1 (en) * 2021-05-24 2022-12-01 Jae-Won Jeon Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof
CN113671196B (zh) * 2021-07-29 2023-09-12 中国人民解放军空军军医大学 Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法
WO2023088440A1 (en) * 2021-11-18 2023-05-25 Correctsequence Therapeutics Regeneration of surface antigen-negative cells
CN114350616A (zh) * 2022-01-24 2022-04-15 深圳市先康达生命科学有限公司 一种免疫细胞及其制备方法和应用
WO2023147293A2 (en) * 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars)
CN119213026A (zh) * 2022-03-04 2024-12-27 耶鲁大学 用于治疗和预防纤维化的方法和组合物
JP2025508050A (ja) * 2022-03-07 2025-03-21 ンカルタ・インコーポレイテッド Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
CN114397464B (zh) * 2022-03-24 2022-06-10 天津德祥生物技术有限公司 一种红细胞膜碎片与载体的偶联复合物、其偶联方法和应用
JP2025511758A (ja) * 2022-04-05 2025-04-16 アルテイア サイエンス エッセ．エッレ．エッレ． 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置
CN114569709B (zh) * 2022-05-05 2022-07-12 苏州慧疗生物医药科技有限公司 高表达adam-28的黑色素瘤自体肿瘤疫苗的制备方法及其应用
CN115951055B (zh) * 2022-12-13 2024-10-15 湖南湘医投蕙尧生命科技有限公司 一种癌症相关蛋白及其抗体和应用
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2025038642A1 (en) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying cd70
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
JP2025074700A (ja) * 2023-10-30 2025-05-14 学校法人藤田学園 抗ｃｄ３８－ｃａｒを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物
CN118108860B (zh) * 2024-03-07 2025-04-29 南京澄实生物医药科技有限公司 一种基于FcRn可提高细胞免疫水平的重组疫苗及应用
PL448316A1 (pl) * 2024-04-24 2025-10-27 Uniwersytet Łódzki Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym
CN119684463B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 抗人ceacam5蛋白的抗体、抗体对和试剂盒及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
WO1994024277A1 (en) 1993-04-13 1994-10-27 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US9982251B2 (en) 2003-03-14 2018-05-29 Cellectis S.A. Large volume ex vivo electroporation method
US20070134796A1 (en) 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP1863909B2 (en) 2005-03-15 2014-09-10 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
WO2007142241A1 (ja) 2006-06-05 2007-12-13 Hiroshima University 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SI2604695T1 (sl) * 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
EP3345620B1 (en) 2009-05-13 2024-08-28 Genzyme Corporation Methods and compositions for treating lupus
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
MX2013004792A (es) 2010-10-27 2013-08-27 Baylor College Medicine Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
EP2877488B1 (en) 2012-07-24 2021-02-24 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
MX367730B (es) 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
DE212016000094U1 (de) * 2015-05-15 2017-12-18 Oru Kayak, Inc. Zusammenfaltbares Kajak mit großem Cockpit

Also Published As

Publication number Publication date
WO2015121454A1 (en) 2015-08-20
CN106029875B (zh) 2025-02-28
NO20161276A1 (en) 2016-08-09
KR102157924B1 (ko) 2020-10-26
MX378913B (es) 2025-03-10
DK3505623T3 (da) 2026-03-09
AU2015216875B2 (en) 2021-02-25
JP2017506636A (ja) 2017-03-09
JP6673838B2 (ja) 2020-04-01
CA2937711C (en) 2020-10-20
BR112016017806A2 (pt) 2017-10-10
ES2711498T3 (es) 2019-05-06
PL3105317T3 (pl) 2019-02-28
US20180201901A1 (en) 2018-07-19
EP3105317A1 (en) 2016-12-21
RU2714258C2 (ru) 2020-02-13
US11692169B2 (en) 2023-07-04
RU2016136702A (ru) 2018-03-19
HUE041497T2 (hu) 2019-05-28
US20230357719A1 (en) 2023-11-09
EP3105317B1 (en) 2018-09-19
DK3105317T3 (en) 2019-01-14
KR20160138404A (ko) 2016-12-05
CN106029875A (zh) 2016-10-12
MX2016010345A (es) 2017-01-23
CA2937711A1 (en) 2016-07-22
US10836998B2 (en) 2020-11-17
IL246645A0 (en) 2016-08-31
IL246645B (en) 2021-02-28
EP3505623A1 (en) 2019-07-03
EP3505623B1 (en) 2025-12-24
TR201819571T4 (tr) 2019-01-21
ES3063961T3 (en) 2026-04-21
PT3105317T (pt) 2019-02-27
US20200407682A1 (en) 2020-12-31
AU2015216875A1 (en) 2016-07-28
RU2016136702A3 (https=) 2018-08-17

Similar Documents

Publication Publication Date Title
US11959091B2 (en) Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
CN106029875B (zh) 为了靶向存在于免疫细胞和病理细胞两者上的抗原而工程化的免疫治疗细胞
US10709775B2 (en) Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
EP3004337B1 (en) Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
EP2997132B1 (en) Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2019149743A1 (en) Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN107075483A (zh) 用于过继细胞治疗的工程改造的细胞
US20230201260A1 (en) Methods for engineering allogeneic and highly active t cell for immunotheraphy
HK40067501A (en) Methods for engineering allogeneic and highly active t cell for immunotheraphy
HK1253706B (en) Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
HK1253706A1 (en) Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
HK1223399B (en) Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
BR112015028483B1 (pt) Método para preparar células t para imunoterapia, e uso de células t modificadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2015, OBSERVADAS AS CONDICOES LEGAIS